Prescription Drug Price Relief Act of 2025

This bill would require the Department of Health and Human Services to check brand-name drug prices at least once a year to see if they are too high. A drug's price would be considered excessive if it costs more in the United States than the middle price charged in Canada, the United Kingdom, Germany, France, and Japan, or if the price is unreasonable based on factors like how much it cost to develop. If a drug is found to be priced too high, the government would remove special rights that keep other companies from making cheaper versions, allow other manufacturers to produce generic or similar versions of the drug, and speed up the approval process for those alternatives. The bill would also require drug companies to publicly report financial details like how much they spend on research and advertising.

Your Vote